DIAGENS-B (02526) made its trading debut today. According to the company's announcement, the IPO price was set at HKD 99 per share, with a total of 7,999,200 shares issued. Each board lot consists of 50 shares, and the net proceeds from the offering amounted to approximately HKD 719.8 million. At the time of writing, the stock was up 121.21%, trading at HKD 219, with a turnover of HKD 181 million.

Public information indicates that DIAGENS-B is deeply engaged in the field of large-scale medical imaging model platforms. In 2025, the company launched its iMedImage® general-purpose medical imaging large model, establishing the world's first cross-modal medical imaging foundation model with hundreds of billions of parameters. Essentially, this model overcomes the limitations of traditional single-modal medical imaging AI. It can cover 19 different medical imaging modalities—including CT, MRI, ultrasound, pathology, and chromosome imaging—addressing over 90% of clinical medical imaging scenarios. This innovation transforms the traditional industry approach of developing solutions from scratch.

With its scale of hundreds of billions of parameters, the model has become the world's largest general-purpose medical imaging foundation model. According to the prospectus, the company's revenue for the first nine months of 2025 surged by 469.8% year-on-year to RMB 112 million, with a gross profit margin as high as 75.9%. The technology licensing business segment achieved a remarkable gross margin of 96.5%, serving as the core driver of revenue growth.

As of September 2025, the company's products have been deployed in more than 400 medical institutions across China. Adoption rates among the country's top ten hospitals—including Peking Union Medical College Hospital and Zhongshan Hospital affiliated with Fudan University—have reached 40%.